Insider Transactions Reported by 15 Insiders of Mereo BioPharma Group plc

Symbol
MREO on Nasdaq
Location
London

There are no Buy or Sell transactions made by insiders since 11 Mar 2025

Mereo BioPharma Group plc executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Rubric Capital Management LP 10%+ Owner $61,076,315 17 Jun 2024
Denise Scots-Knight Chief Executive Officer, Director $833,250 01 Feb 2026
Charles Sermon General Counsel $264,620 01 Feb 2026
Christine Ann Fox Chief Financial Officer $264,620 01 Feb 2026
Alexandra Hughes-Wilson Chief Patient Access and Commercial Planning $155,540 01 Feb 2026
John A. Lewicki Chief Scientific Officer $117,160 01 Feb 2026
Marc J. Yoskowitz Director $55,550 26 Feb 2026
MICHAEL S. WYZGA Director $55,550 26 Feb 2026
Jeremy Bender Director $55,550 26 Feb 2026
Pierre Jacquet Director $55,550 26 Feb 2026
Anders Ekblom Director $55,550 26 Feb 2026
Annalisa Jenkins Director $55,550 26 Feb 2026
DEEPIKA PAKIANATHAN Director $55,550 26 Feb 2026
Daniel Shames Director $55,550 26 Feb 2026
Justin Hunter Roberts Director 01 Jan 2024

Recent Insider Transactions by Companies or Individuals for Mereo BioPharma Group plc

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.